Russian Cancer Drug Supplies Fail Demand

28 October 1996

The number of cancer patients in the Russian Federation has been rising steadily, but neither domestic anticancer drug production nor imports have been sufficient to match demand, reports Meditsinskiye Novosti.

Domestic output meets only 11% of requirements, while imports are said to be "far below actual needs."

The current oncological market offers 138 antitumor agents of various types, with over 25% made up of alkylating agents, 11% antitumor antibiotics, 9% antimetabolite products, 10% "natural-based" drugs and enzymes, 17% hormonal drugs and close to 15% leukopoiesis stimulators.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight